Literature DB >> 12768081

Primary hyperoxaluria: genotype-phenotype correlation.

Doroti Pirulli1, Martino Marangella, Antonio Amoroso.   

Abstract

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder caused by a deficiency of alanine-glyoxylate aminotransferase (AGT), which is encoded by a single copy gene (AGXT). Molecular diagnosis was used in conjunction with clinical, biochemical and enzymological data to evaluate genotype-phenotype correlation. Patients can present a severe form of PH1, an adult form and a mild to moderate decrease in renal function. Biochemical diagnosis is made by plasma, urine and dialyzate oxalate and glycolate assays, and by liver AGT activity and pyridoxine responsitivity. Molecular genetic diagnosis can be made using different techniques, for example, the single strand conformation polymorphism technique (SSCP), followed by the sequencing of the 11 AGXT exons. The disease is clinically and genetically classified as highly heterogeneous. Mutant alleles can be recognised in 80- 90% of chromosomes, depending on the techniques used. Mutations in exons 1, 2, 4 and 10 are more frequent in Italian patients. Normalized AGT activity seems to be lower in the severe form than in the adult form. Double heterozygous patients present a lower age at disease onset and they were more frequent in the more severe than in mild severe disease. The 444T>C mutation was more frequent in the severe form, while the opposite was observed for 630G>A. 630G>A mutation homozygotes had a higher AGT residual activity. The presence of allelic heterogeneity of the AGXT could be responsible, to some extent, for the phenotypic heterogeneity in PH1. Homozygous genotypes were more frequent than expected and were associated with a less severe form of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 12768081

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  8 in total

1.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Authors:  Katharina Hopp; Andrea G Cogal; Eric J Bergstralh; Barbara M Seide; Julie B Olson; Alicia M Meek; John C Lieske; Dawn S Milliner; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

2.  Primary hyperoxaluria type 1 with a novel mutation.

Authors:  Sidharth Kumar Sethi; Hans R Waterham; Sonika Sharma; Alok Sharma; Pankaj Hari; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

Review 3.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

Review 4.  Optic atrophies in metabolic disorders.

Authors:  Marjan Huizing; Brian P Brooks; Yair Anikster
Journal:  Mol Genet Metab       Date:  2005-09-27       Impact factor: 4.797

Review 5.  The primary hyperoxalurias.

Authors:  Bernd Hoppe; Bodo B Beck; Dawn S Milliner
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

6.  Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis.

Authors:  Susan Ruth Marengo; Daniel H-C Chen; Andrew P Evan; Andre J Sommer; Nicholas T Stowe; Donald G Ferguson; Martin I Resnick; Gregory T MacLennan
Journal:  Urol Res       Date:  2006-02-15

7.  Human wild-type alanine:glyoxylate aminotransferase and its naturally occurring G82E variant: functional properties and physiological implications.

Authors:  Barbara Cellini; Mariarita Bertoldi; Riccardo Montioli; Alessandro Paiardini; Carla Borri Voltattorni
Journal:  Biochem J       Date:  2007-11-15       Impact factor: 3.857

Review 8.  Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I.

Authors:  Angel L Pey; Armando Albert; Eduardo Salido
Journal:  Biomed Res Int       Date:  2013-07-16       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.